Plasma-derived therapeutics manufacturer scaling production and quality digitalization
Octapharma France operates one of two French production sites for a global plasma fractionation business serving 120 countries across immunotherapy, hematology, and critical care. The tech stack—SAP ERP, LIMS, MES, SCADA, and nascent Power Platform adoption—reflects a manufacturing-heavy operation now digitizing quality workflows and batch record management. Hiring is concentrated in manufacturing (17 open roles) and quality (11), with 25 positions posted in the last 30 days; the intern-heavy junior pipeline suggests skill-building for upcoming capex and greenfield plant projects.
Notable leadership hires: Lead Engineer
Octapharma France is part of the world's largest independent private plasma fractionation company, established in 1983. The Lingolsheim site operates as a production and R&D node within a global network of five manufacturing plants and seven R&D centers. The company manufactures high-purity plasma-derived drugs and recombinant products from human plasma and cell lines, supporting patient treatment in 120 countries. Core therapeutic areas are immunotherapy, hematology, and critical care. The organization maintains over 11,000 employees globally and operates 190+ plasma donation centers across Europe and North America.
Octapharma France manufactures plasma-derived and recombinant therapeutic drugs for immunotherapy, hematology, and critical care. The Lingolsheim facility is one of two French production sites serving 120 countries.
Primary systems include SAP ERP, LIMS, MES, SCADA, and DCS for production and quality. BI tools are Power BI and Qlik Sense. The company is adopting Power Platform and undertaking LIMS migration and microbiology module implementation.
Other companies in the same industry, closest in size